/ /

CLINICAL

VMA associated with poor outcomes in anti-VEGF-treated patientsThe presence of vitreomacular adhesion (VMA) is associated with poorer, short-term anatomic, and functional outcomes in eyes with diabetic macular edema (DME) receiving anti-VEGF therapy, according to Márcio B. Nehemy, MD, PhD.
Reviewing anterior segment ARVO 2017 postersSo much basic science research is presented at this meeting, and most of it will be years before it makes its way to clinical trials. Let’s concentrate on research that might be of use to us in the exam room very soon.
The Alcon DAILIES® AQUACOMFORT PLUSFor many eye care professionals (ECPs), helping patients see, look and feel their best means being able to offer their patients daily disposable contact lenses. The DAILIES® Choice Program is an opportunity to provide patients with a convenient alternative to weekly and monthly replacement lenses by reducing the price barrier for new wearers with up to $200 in savings on a year’s supply of DAILIES® lenses.
Dry eye checklist may help ODs treat patients more efficiently
Dry eye checklist may help ODs treat patients more efficientlyScott Schachter, OD, discusses dry eye and how incorporating a dry eye checklist may help improve patient treatment.
IOL selection important in patients with retinal diseaseWhen dealing with patients with retinal disease, macular disease, or a meaningful risk of retinal detachment, certain types of IOLs should be avoided due to potential complications.
How to manage vision changes over time post-LASIK
How to manage vision changes over time post-LASIKHow often have you heard a post-LASIK patient say his surgery “isn’t working anymore” or it has “expired?” While the corneal tissue that was ablated is gone forever, eyes can change over time, and laser vision correction does not stop time.
Teleglaucoma redefining role in future of blindness prevention'Teleglaucoma’ is feasible and can play a major role in blindness prevention. Telemedicine and teleglaucoma are going to be an important part of how physicians take care of patients in the United States and worldwide.
Glaucoma, dry eye drugs center of pharmaceutical opportunitiesThe pharma drought is coming to a close. After decades of same-old medications for glaucoma and ocular surface disease, a series of new agents with new mechanisms of action (MOA) are moving toward marketing approval.
Aerie’s focus on therapies that address cause of vision lossAerie Pharmaceuticals is developing the first novel mechanism of action for the treatment of glaucoma in over 20 years. The company is developing two products for the treatment of patients with glaucoma and ocular hypertension. One is an entirely new agent, netarsudil, the other is a combination of netarsudil plus latanoprost.
B + L places focus on innovation in pharma, surgical, vision careBausch + Lomb (B + L) is more than one of the oldest eye care companies in the industry. It is also one of the broadest, with portfolios in contact lenses, consumer eye products, cataract surgery, intraocular lenses, retina surgery, and a wide range of ophthalmic pharmaceutical products.